Avadel Pharmaceuticals PLC (ADR)  

(Public, NASDAQ:FLML)   Watch this stock  
Find more results for FLML
0.00 (0.00%)
Real-time:   4:00PM EST
NASDAQ real-time data - Disclaimer
Currency in USD
Range     -
52 week 7.56 - 15.45
Open     -
Vol / Avg. 0.00/92,920.00
Mkt cap 405.81M
P/E 33.25
Div/yield     -
EPS 0.31
Shares 41.24M
Beta 1.45
Inst. own 72%

Key stats and ratios

Q3 (Sep '17) 2016
Net profit margin 54.64% -27.47%
Operating margin 65.83% -3.30%
EBITD margin - 39.14%
Return on average assets 32.41% -17.92%
Return on average equity 100.41% -74.24%
Employees 165 -
CDP Score - -


Blanchardstown Corporate Park, Block 10
+353-1-4851200 (Phone)
+353-1-5261077 (Fax)

Website links

External links

Analyst Estimates - MarketWatch
SEC Filings - EDGAR Online
Major Holders - MSN Money


Avadel Pharmaceuticals, PLC is a specialty pharmaceutical company. The Company offers various drug delivery platforms, including Micropump, LiquiTime, Trigger Lock and Medusa. The Company offers its products in various categories, including hospital, including Bloxiverz, Vazculep and Akovaz, and pediatrics, including Karbinal ER, Cefaclor for Oral Suspension, AcipHex Sprinkle and Flexichamber. Bloxiverz is a drug used intravenously in the operating room for the reversal of the effects of non-depolarizing neuromuscular blocking agents after surgery. Vazculep is used to treat clinically hypotension resulting primarily from vasodilation in the setting of anesthesia. Akovaz is indicated to treat clinically hypotension in the setting of anesthesia. Cefaclor is indicated for the treatment of otitis media, lower respiratory infections, pharyngitis and tonsillitis, urinary tract infections, and skin and skin structure infections, caused by susceptible organisms.

Officers and directors

Michael S. Anderson Chief Executive Officer, Director
Age: 68
Bio & Compensation  - Reuters
Michael F. Kanan Senior Vice President, Chief Financial Officer
Age: 53
Bio & Compensation  - Reuters
Gregory J. Divis Jr. Executive Vice President, Chief Commercial Officer
Age: 50
Bio & Compensation  - Reuters
Phillandas T. Thompson Senior Vice President, General Counsel, Corporate Secretary
Age: 42
Bio & Compensation  - Reuters
Sandra L. Hatten Senior Vice President - Quality and Regulatory Affairs
Age: 59
Bio & Compensation  - Reuters
David P. Gusky Chief Accounting Officer, Corporate Controller
Age: 40
Bio & Compensation  - Reuters
Dhiren D'Silva Vice President - Irish and European Operations
Age: 43
Bio & Compensation  - Reuters
David Monteith Vice President - Research & Development
Age: 52
Bio & Compensation  - Reuters
Craig R. Stapleton Non-Executive Independent Chairman of the Board
Age: 71
Bio & Compensation  - Reuters
Guillaume Cerutti Independent Director
Age: 50
Bio & Compensation  - Reuters